UroGen Pharma Ltd.: insider trades · United States · SEC (Form 4)

About UroGen Pharma Ltd.

UroGen Pharma Ltd. is a U.S.-listed biopharmaceutical company traded on NASDAQ under the ticker URGN in the United States (United States). The company is focused on urology, with a particular emphasis on uro-oncology and other specialty urologic diseases that still have meaningful unmet medical needs. UroGen was founded in 2004 and is headquartered in Princeton, New Jersey, with additional operations in Israel. From an equity-investor perspective, the business is best understood as a specialty biotech rather than a diversified pharmaceutical group. ([investors.urogen.com](https://investors.urogen.com/resources/overview/?utm_source=openai)) UroGen’s core differentiator is its proprietary RTGel® reverse-thermal hydrogel platform. RTGel is designed to enable sustained local delivery of medicines in the urinary tract, helping drugs remain in contact with the target tissue for longer periods. That technology underpins both approved products and future pipeline programs, and it is central to the company’s commercial and scientific identity. UroGen positions RTGel as a way to improve therapeutic profiles of existing drugs and to support non-surgical treatment options in anatomically complex urologic settings. ([urogen.com](https://www.urogen.com/our-portfolio?utm_source=openai)) The company’s commercial portfolio currently includes JELMYTO® and ZUSDURI™. JELMYTO is mitomycin for pyelocalyceal solution and is used in low-grade upper tract urothelial cancer. ZUSDURI, mitomycin for intravesical solution, is described by UroGen as the first and only FDA-approved medicine for adults with recurrent, low-grade, intermediate-risk non-muscle invasive bladder cancer. This makes UroGen highly focused on a narrow set of urothelial indications where product differentiation, regulatory exclusivity, and specialist physician adoption can matter more than broad primary-care scale. ([urogen.com](https://www.urogen.com/our-portfolio?utm_source=openai)) In competitive terms, UroGen occupies a niche position in uro-oncology. It is not trying to compete across broad oncology categories; instead, it targets defined urologic segments where alternative treatments may be invasive, cumbersome, or less well suited to localized delivery. The company’s pipeline strategy is built around next-generation mitomycin-based assets such as UGN-103 and UGN-104, which are intended to extend the franchise and support lifecycle management around the RTGel platform. That pipeline strategy is important because it can broaden the commercial runway beyond the current marketed products. ([investors.urogen.com](https://investors.urogen.com/news-releases/news-release-details/urogen-announces-zusduritm-launch-track-and-reports-fourth/?utm_source=openai)) Recent developments have been especially important. In 2025, UroGen reported FDA approval and commercial launch activity for ZUSDURI, marking a major transition from a development-led story toward a more commercial one. The company also continued to publish clinical and durability data supporting its lead programs, while management highlighted 2026 as a pivotal year for the launch trajectory. For investors, the key themes are execution, reimbursement, uptake by urology practices, and the company’s ability to convert its regulatory milestones into durable revenue growth. ([investors.urogen.com](https://investors.urogen.com/news-releases/news-release-details/urogen-announces-zusduritm-launch-track-and-reports-fourth?utm_source=openai))